SAN RAMON, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2022. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a virtual session scheduled to begin at 2:40 PM ET.
The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$79.51 |
Daily Change: | 1.28 1.64 |
Daily Volume: | 2,064,273 |
Market Cap: | US$15.870B |
March 06, 2025 December 17, 2024 December 05, 2024 September 03, 2024 August 28, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load